ArticleThe Journal of experimental medicine1999
Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.
Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 123 citations in OpenAlex.
- Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.Cancer immunology, immunotherapy : CII · 2005Trial
- Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.Cancer immunology, immunotherapy : CII · 2003Trial
- Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.Journal for immunotherapy of cancer · 2024Article
- Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.Journal for immunotherapy of cancer · 2023Article
- Review
- TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation.Asian journal of pharmaceutical sciences · 2020Article
- A Preliminary Study of the Cross-Reactivity of Canine MAGE-A with Hominid Monoclonal Antibody 6C1 in Canine Mammary Gland Tumors: An Attractive Target for Cancer Diagnostic, Prognostic and Immunotherapeutic Development in Dogs.Veterinary sciences · 2020Article
- Opportunities and Challenges for Antibodies against Intracellular Antigens.Theranostics · 2019Review
- Opportunities and challenges for TCR mimic antibodies in cancer therapy.Expert opinion on biological therapy · 2016Review
- Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Filamentous bacteriophage fd as an antigen delivery system in vaccination.International journal of molecular sciences · 2012Review
- Article
- Generation of MHC class I ligands in the secretory and vesicular pathways.Cellular and molecular life sciences : CMLS · 2011Review
- A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells.Cancer research · 2009Article
- Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Specific CD8(+ )T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination.Cancer immunology, immunotherapy : CII · 2007Article
- Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.Cancer immunology, immunotherapy : CII · 2007Article
- Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have analyzed the presentation of human histocompatability leukocyte antigen-A*0201-associated tumor peptide antigen MAGE-3271-279 by melanoma cells. We show that specific cytotoxic T lymphocyte (CTL)-recognizing cells transfected with a minigene encoding the preprocessed fragment MAGE-3271-279 failed to recognize cells expressing the full length MAGE-3 protein. Digestion of synthetic peptides extended at the NH2 or COOH terminus of MAGE-3271-279 with purified human proteasome revealed that the generation of the COOH terminus of the antigenic peptide was impaired. Surprisingly, addition of lactacystin to purified proteasome, though partially inhibitory, resulted in the generation of the antigenic peptide. Furthermore, treatment of melanoma cells expressing the MAGE-3 protein with lactacystin resulted in efficient lysis by MAGE-3271-279-specific CTL. We therefore postulate that the generation of antigenic peptides by the proteasome in cells can be modulated by the selective inhibition of certain of its enzymaticactivities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.